中国临床医学2025，Vol.32Issue(2)：295-299,5.DOI:10.12025/j.issn.1008-6358.2025.20241038
免疫检查点抑制剂相关大疱性类天疱疮研究进展:从发病机制到诊疗策略
Pathogenesis,diagnosis and treatment of immune checkpoint inhibitor related bullous pemphigoid
孙毅 1杨骥1
作者信息
- 1. 复旦大学附属中山医院皮肤科,上海 200032
- 折叠
摘要
Abstract
As a new type of anti-tumor therapy,immune checkpoint inhibitor(ICI)can effectively improve the survival rate of tumor patients,but also bring a series of adverse reactions.Among these,immune-related cutaneous adverse events are prevalent.There is a relatively low incidence of bullous pemphigoid(BP)induced by ICI.However,this adverse event may not only negatively impact patient quality of life of patient,but also lead to treatment interruptions or discontinuations.This paper reviews the pathogenesis,prevalence,clinical manifestations,management methods of BP induced by ICI and its effect on tumor immunotherapy.关键词
大疱性类天疱疮/免疫检查点抑制剂/肿瘤免疫治疗/皮肤不良反应Key words
bullous pemphigoid/immune checkpoint inhibitor/tumor immunotherapy/cutaneous adverse reaction分类
临床医学引用本文复制引用
孙毅,杨骥..免疫检查点抑制剂相关大疱性类天疱疮研究进展:从发病机制到诊疗策略[J].中国临床医学,2025,32(2):295-299,5.
